Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 153 Melanoma 133 Lymphoma 124 Prostatic Neoplasms 123 Carcinoma, Non-Small-Cell Lung 113 Multiple Myeloma 106 Carcinoma, Renal Cell 92 Ovarian Neoplasms 88 Leukemia, Myeloid, Acute 83 Sarcoma 82 Lung Neoplasms 80 Leukemia, Lymphocytic, Chronic, B-Cell 80 Leukemia 79 Colorectal Neoplasms 79 Colonic Neoplasms 74 Rectal Neoplasms 71 Lymphoma, Non-Hodgkin 69 Pancreatic Neoplasms 68 Carcinoma, Ovarian Epithelial 66 Neoplasms 65 Lymphoma, Large B-Cell, Diffuse 65 Brain Neoplasms 65 Precursor Cell Lymphoblastic Leukemia-Lymphoma 64 Lymphoma, Follicular 58 Kidney Neoplasms 58 Glioblastoma 57 Fallopian Tube Neoplasms 54 Carcinoma, Hepatocellular 51 Lymphoma, Mantle-Cell 50 Central Nervous System Neoplasms 50

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NIH × Proteus Syndrome × Clear all

NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡